Please login to the form below

Not currently logged in
Email:
Password:

UDG Healthcare acquires two New-York-based healthcare agencies

Offers a combined total of $82.4m for Create NYC and SmartAnalyst

UDG HealthcareHealthcare services provider UDG Healthcare has acquired two New-York based agencies earlier this week, offering a collective sum of up to $82.4m.

The Dublin-headquartered company operates across three divisions – Ashfield, Sharp and Aquilant – and currently employs 9,000 people with operations in 24 countries.

It has recently expanded its US footprint however, with its newly-acquired creative communications agency CreateNYC.

That business will soon operate as a division of Ashfield - UDG's healthcare communications arm.

Founded in 2009 by Natalie McDonald – who will remain with the company as its chief executive following its transition – CreateNYC employs 43 people and offers execution of sales and marketing materials for its pharmaceutical clients.

Meanwhile, UDG Healthcare’s additional acquisition SmartAnalyst provides strategic consulting services to pharmaceutical and biotech companies.

It was founded in 2001 and has grown to house 135 employees based in multiple countries, including London and New York.

The company also offers clients Health Economic and Outcomes Research (HEOR) services, a function that is in line with Ashfield’s strategy to expand its advisory service.

Commenting on the new purchases, Brendan McAtamney (pictured) chief executive of UDG Healthcare said: “These two acquisitions further expand the services we offer our healthcare clients.

Brendan Mcatamney

“CreateNYC adds innovative, creative services within Ashfield Communications while SmartAnalyst expands Ashfield’s advisory pillar, adding new capabilities in strategic consulting and HEOR.

“Both transactions meet all of UDG’s acquisition criteria – they are a good strategic and cultural fit; meet our target financial hurdle rates and involves an expansion of our current capabilities.”

Following the news, the FTSE 250 company’s share price rose by 2%.

Article by
Gemma Jones

6th July 2018

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...